<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163756">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966355</url>
  </required_header>
  <id_info>
    <org_study_id>TPSTOT</org_study_id>
    <nct_id>NCT00966355</nct_id>
  </id_info>
  <brief_title>Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding</brief_title>
  <official_title>RCT for the Effect of Early Administration of Vasoactive Substances When Combined With Endoscopic Treatment in Acute Gastro-esophageal Variceal Bleeds: Comparisons Among Terlipressin, Somatostatin, and Octreotide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients who are suspected to have variceal bleedings, pharmacologic therapy with
      vasoactive drugs such as terlipressin, somatostatin, and octreotide is recommended as soon
      as possible, even before endoscopy. However, it is still unclear whether the efficacies of
      these drugs are same or not. This study is performed to compare the efficacy of
      terlipressin, somatostatin, and octreotide in patients with variceal bleeding for the
      control of variceal bleeding in combination with endoscopic therapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2006</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-day treatment failure (failure to control bleeding, rebleeding, or death)</measure>
    <time_frame>5 days after enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Proportion of active bleeding during first endoscopic examination • Blood units transfused for 5 days • Adverse effects</measure>
    <time_frame>5 days after enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">822</enrollment>
  <condition>Variceal Bleeding, Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Terlipressin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treat with terlipressin IV for 5 days and endoscopic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Somatostatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treat with somatostatin IV for 5 days and endoscopic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Octreotide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treat with octreotide IV for 5 days and endoscopic treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days</description>
    <arm_group_label>Terlipressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatostatin</intervention_name>
    <description>loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days</description>
    <arm_group_label>Somatostatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <description>loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days</description>
    <arm_group_label>Octreotide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  liver cirrhosis

          -  age between 16 and 75 years

          -  Patients who have upper GI bleeding symptoms (hematemesis or melena) within 24 hours
             before enrollment

          -  Patients whose systolic blood pressure &lt;100 mmHg or pulse rate &gt;100/min at the
             enrollment

          -  Patients who were not performed endoscopic or pharmacologic therapy for varices

          -  Signed informed consent

        Exclusion Criteria:

          -  Pregnancy

          -  Positive anti-HIV Ab

          -  A history of severe side-effects or contraindications to study drugs

          -  Severe cardiovascular diseases: acute myocardial infarction, A-V block, congestive
             heart failure, ischemic heart disease, hypertension (systolic blood pressure &gt;170
             mmHg or diastolic pressure &gt;100 mmHg)

          -  Chronic renal failure

          -  Hepatocellular carcinoma with protal vein thrombosis

          -  Coexisting malignancy except hepatocellular carcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soon Ho Um, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soon Ho Um, Prof</last_name>
    <phone>82-2-920-5019</phone>
    <email>umsh@korea.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yeon Seok Seo, MD</last_name>
    <phone>82-2-920-6608</phone>
    <email>drseo@korea.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yeon Seok Seo, MD</last_name>
      <phone>82-2-920-6608</phone>
      <email>drseo@korea.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <lastchanged_date>August 25, 2009</lastchanged_date>
  <firstreceived_date>August 25, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Liver Cirrhosis Clinical Research Center, Division of Gastroenterology and Hepatology, Department of Internal Medicine</name_title>
    <organization>Korea University Anam Hospital</organization>
  </responsible_party>
  <keyword>Cirrhosis, Esophagus Disorders, Varicose Veins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Somatostatin</mesh_term>
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
